deltatrials
Completed PHASE3 NCT00095134

Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

A Double-Blind Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

Sponsor: Janssen, LP

Conditions Major Depressive Disorder
Interventions risperidone
Updated 6 times since 2017 Last updated: Dec 5, 2011 Started: Oct 31, 2004 Completion: Nov 30, 2005

A PHASE3 clinical study on Major Depressive Disorder, this trial is completed. The trial is conducted by Janssen, LP and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Janssen, LP
  • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Data source: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States, Alliance, United States, Arlington Heights, United States, Avon, United States, Beaumont, United States, Birmingham, United States, Burbank, United States, Cadillac, United States, Canal Fulton, United States, Cincinnati, United States and 53 more location s